Back
Pregnancy after breast cancer: Are young patients willing to participate in clinical studies?
Journal article

Pregnancy after breast cancer: Are young patients willing to participate in clinical studies?

  • Pagani O Oncology Institute of Southern Switzerland (IOSI), 6500 Bellinzona, Switzerland; International Breast Cancer Study Group (IBCSG), Effingerstrasse 40, 3008 Bern, Switzerland. Electronic address: olivia.pagani@ibcsg.org.
  • Ruggeri M International Breast Cancer Study Group (IBCSG), Effingerstrasse 40, 3008 Bern, Switzerland.
  • Manunta S Oncology Institute of Southern Switzerland (IOSI), 6500 Bellinzona, Switzerland.
  • Saunders C School of Surgery, University of Western Australia, Perth, WA 6009, Australia.
  • Peccatori F Fertility & Procreation Unit, Division of Gynecologic Oncology, European Institute of Oncology (IEO), Via Ripamonti 435, 20141 Milan, Italy.
  • Cardoso F Breast Unit, Champalimaud Cancer Centre, Av. De Brasília, Doca de Pedrouços, 1400 - 038 Lisbon, Portugal.
  • Kaufman B Breast Cancer Service for Young Women, Oncology Institute, Sheba Medical Center, Tel Hashomer, 52621, Israel.
  • Paluch-Shimon S Breast Cancer Service for Young Women, Oncology Institute, Sheba Medical Center, Tel Hashomer, 52621, Israel.
  • Gewefel H Woman and Fetal Imaging Clinic (WAFI), 2 Mohamed Farid Wagdy St., Suite41 Manial Al Roda Island, Cairo, Egypt.
  • Gallerani E Ospedale Multimedica, Viale Piemonte 70, Castellanza, VA, Italy.
  • Abulkhair OM Department of Oncology, King Abdul Aziz Medical City for National Guard, Riyadh, Saudi Arabia.
  • Pistilli B Oncology Department Macerata Hospital, Via S. Lucia 1, 62100 Macerata, Italy.
  • Warner E Sunnybrook Health Sciences Centre, Odette Cancer Centre, Medical Oncology, 2075 Bayview Avenue, Toronto, ON M4N 3M5, Canada.
  • Saloustros E Hereditary Cancer Clinic, Dpt of Medical Oncology, University Hospital of Heraklion, Voutes, Box 1352, Heraklion 71110, Greece.
  • Perey L Greeceo Unité d'oncologie, Ensemble hospitalier de la Côte, Hôpital de Morges, Morges and Centre pluridisciplinaire d'oncologie (CePO), CHUV, Lausanne, Switzerland.
  • Zaman K CHUV-Centre d'Oncologie, Rue du Bugnon 46, 1011 Lausanne, Switzerland.
  • Rabaglio M Universitätsklinik und Poliklinik für Medizinische Onkologie/Brust-und Tumor Zentrum der Frauenklinik, Inselspital, Freiburgstrasse, 3010 Bern, Switzerland.
  • Gelber S IBCSG Statistical Center, Dana-Farber Cancer Institute, Frontier Science and Technology Research Foundation, Boston, MA, USA.
  • Gelber RD IBCSG Statistical Center, Dana-Farber Cancer Institute, Frontier Science and Technology Research Foundation, Boston, MA, USA.
  • Goldhirsch A International Breast Cancer Study Group (IBCSG), Effingerstrasse 40, 3008 Bern, Switzerland; Program of Breast Health, European Institute of Oncology (IEO), Via Ripamonti, 435, 20141 Milano, Italy.
  • Korde L Division of Medical Oncology, University of Washington, Seattle, WA, USA.
  • Azim HA Department of Medicine, BrEAST Data Centre, Institut Jules Bordet, Université Libre de, Bruxelles, Brussels, Belgium.
  • Partridge AH Dana-Farber Cancer Institute, 450 Brookline Avenue, Yawkey 12, Boston, MA 02215, USA.
Show more…
  • 2015-02-10
Published in:
  • Breast (Edinburgh, Scotland). - 2015
Breast cancer
Endocrine treatment
Estrogen receptor
Pregnancy
Young patients
Adult
Age Factors
Breast Neoplasms
Clinical Trials as Topic
Feasibility Studies
Female
Fertility Preservation
Humans
Patient Participation
Pregnancy
Pregnancy Complications, Neoplastic
Receptors, Estrogen
Surveys and Questionnaires
Withholding Treatment
English Young patients with breast cancer (BC) are often concerned about treatment-induced infertility and express maternity desire. Conception after BC does not seem to affect outcome, but information in estrogen-receptor positive (ER+) disease is not definitive. From September 2012-March 2013, 212 evaluable patients with ER+ early BC, <37 years at diagnosis, from 5 regions (Europe/US/Canada/Middle-East/Australia) answered a survey about fertility concerns, maternity desire and interest in a study of endocrine therapy (ET) interruption to allow pregnancy. Overall, 37% of respondents were interested in the study; younger patients (≤30 years) reported higher interest (57%). Motivation in younger patients treated >30 months was higher (83%) than in older women (14%), interest was independent of age in patients treated for ≤30 months. A prospective study in this patient population seems relevant and feasible. The International-Breast-Cancer-Study-Group (IBCSG), within the Breast-International-Group (BIG) - North-American-Breast-Cancer-Groups (NABCG) collaboration, is launching a study (POSITIVE) addressing ET interruption to allow pregnancy.
Language
  • English
Open access status
closed
Identifiers
Persistent URL
https://folia.unifr.ch/global/documents/57852
Statistics
Document views: 41 File downloads: